Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

392
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
392
T Cell Types and Functions01:24

T Cell Types and Functions

2.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

403
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
403

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perceptions of Glucagon-like Peptide 1 Receptor Agonists Among Individuals With Knee Osteoarthritis and Excess Weight: A Qualitative Study.

ACR open rheumatology·2026
Same author

Longitudinal patterns of C-reactive protein values in calcium pyrophosphate deposition disease.

Scandinavian journal of rheumatology·2026
Same author

Analytic challenges in defining structural phenotypes in OA clinical trials: a perspective.

Osteoarthritis imaging·2026
Same author

The role of radiography and MRI as screening tools and outcome measures in clinical trials of knee osteoarthritis: a perspective on the current status and outlook.

Therapeutic advances in musculoskeletal disease·2026
Same author

Magnetic Resonance Imaging Biomarkers of Knee Osteoarthritis Progression.

ACR open rheumatology·2025
Same author

The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity.

Annals of internal medicine·2025

Related Experiment Video

Updated: Dec 28, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

895

Predicting Remission Among Patients With Rheumatoid Arthritis Starting Tocilizumab Monotherapy: Model Derivation and

Jamie E Collins1, Fredrik D Johansson2, Sara Gale3

  • 1Brigham and Women's Hospital, Boston, Massachusetts.

ACR Open Rheumatology
|February 12, 2020
PubMed
Summary

A new prediction score identifies rheumatoid arthritis (RA) patients likely to achieve remission with tocilizumab (TCZ) monotherapy. This tool aids clinicians in tailoring RA treatment based on patient characteristics for better outcomes.

More Related Videos

Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

2.1K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.9K

Related Experiment Videos

Last Updated: Dec 28, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

895
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

2.1K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.9K

Area of Science:

  • Rheumatology
  • Clinical Trial Analysis
  • Predictive Modeling

Background:

  • Many rheumatoid arthritis (RA) patients seek to move beyond methotrexate combinations.
  • Identifying patients likely to achieve remission with tocilizumab (TCZ) monotherapy is crucial for personalized treatment.

Purpose of the Study:

  • To develop and validate a prediction model and remission score for TCZ monotherapy in RA patients.
  • To identify key clinical factors associated with achieving remission.

Main Methods:

  • Analysis of four TCZ monotherapy randomized controlled trials in RA.
  • Logistic regression used to identify predictors of remission (defined as CDAI < 2.8 at 24 weeks).
  • Model derivation and internal validation performed, followed by combined cohort analysis for a remission prediction score.

Main Results:

  • Key predictors for remission included younger age, male sex, lower baseline CDAI and HAQ-DI scores, shorter RA duration, specific regions, no prior DMARD/methotrexate exposure, and baseline hematocrit.
  • The prediction model demonstrated good performance (AUC 0.739 in derivation, 0.756 in validation).
  • Patients were categorized into low, intermediate, and moderate remission probability groups based on the score.

Conclusions:

  • An easily accessible remission prediction score was developed to predict RA remission at 24 weeks with TCZ monotherapy.
  • This score can assist clinicians in personalizing RA treatment strategies based on patient profiles.